RVF and Other Emerging Infectious Diseases in East and Central Africa
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age2+
SponsorWashington State University
About this trial
Rift Valley fever (RVF), a disease transmitted from livestock (cattle, sheep, goats, camels) to humans more commonly occurs in the East and Central Africa (ECA) regions where more than 15 major epidemics affecting more than one country have been reported over the past 50 years. Within the region, there are specific areas, referred to as hotspots, which support RVF virus maintenance via low-level virus circulation between animals, humans, and mosquitoes. Most outbreaks originate from these hotspots. Our goal is to conduct studies in RVF hotspots in four ECA countries, Kenya, Uganda, Tanzania, and Democratic Republic of Congo (DRC) to determine the burden of RVF disease among humans, wildlife and livestock during inter-epidemic periods (IEPs) and discover circulation of undetected infectious diseases. This information is important for use in developing an early warning system and possibly a vaccination strategy. The study will take place in Uganda, Kenya, Tanzania and Democratic Republic of Congo
Eligibility criteria
This trial accepts healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
For health facility based study: Patients attending enrolled health facilities in study areas i.e. North and South Kivu (DRC), Isingiro, Rubanda and Kabale districts (Uganda), Muranga, Isiolo, Tana River and Marsabit counties (Kenya) and Iringa district (Tanzania). For community cross sectional survey: Residents of households in study areas i.e. North and South Kivu (DRC), Isingiro, Rubanda and Kabale districts (Uganda), Muranga, Isiolo, Tana River and Marsabit counties (Kenya) and Iringa district (Tanzania).
Trial design
Design model
Other
Time perspective
Other
Treatments tested in this trial
Evidence of past or recent RVF exposure
Other interventionDetection of RVF exposure.
Treatment groups
5,000 Participants
are divided into 2 treatment groupsGroup A: Health facility based cohort1 intervention
Group B: Community survey1 intervention
Trial outcomes
Primary outcomes
1
Detection of RVF virus exposure
Detection of RVFV RNA, and IgM and IgG antibodies
Time frame
2 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Washington State University
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator
Emory University
Collaborator
Washington University School of Medicine
Collaborator
Kenya Medical Research Institute
Collaborator
University of Nairobi
Collaborator
The International Livestock Research Institute (ILRI)
Collaborator
MRC/UVRI and LSHTM Uganda Research Unit
Collaborator
Sokoine University of Agriculture
Collaborator
Institut National de Recherche Biomedicale (INRB)
Collaborator
Institute of Tropical Medicine, Belgium
Collaborator
Charite University, Berlin, Germany
Collaborator
Kenya Ministry of Health
Collaborator
Ministry of Agriculture Livestock Fisheries and Cooperatives, Kenya
Collaborator
Ministry of Agriculture, Animal Industry and Fisheries, Uganda
Collaborator
Ministry of Health, Uganda
Collaborator
Ministry of Public Health, Democratic Republic of the Congo
Collaborator
Source ClinicalTrials.gov